Memantina Alter

Memantine, the active ingredient in Memantina Alter, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adults, helping to improve cognition and daily functioning.

GNH USA supplies Memantina Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with consistent quality and regulatory compliance across EU markets. The company ensures reliable supply chains, appropriate documentation, and responsive customer support for global procurement.

Memantine is an NMDA receptor antagonist used in the management of neurodegenerative disorders.

Alzheimer’s disease (moderate to severe): improves cognition and global clinical status Alzheimer’s disease (mild to moderate): may be added to cholinesterase inhibitors to support cognition Alzheimer’s disease (behavioral symptoms): may help reduce agitation and aggression

Common Side Effects: - Dizziness: transient light‑headedness, especially after dose initiation - Headache: mild to moderate intensity, often resolves with continued therapy - Constipation: reduced bowel movements, manageable with dietary fiber - Confusion: occasional disorientation, particularly in elderly patients - Somnolence: mild sleepiness, may improve over time

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis - Seizures: rare but may occur, especially with high plasma levels - Hallucinations or psychosis: uncommon, warrant immediate medical review - Cardiac arrhythmias: rare cases of QT prolongation reported - Hepatic dysfunction: elevated liver enzymes in isolated reports

Memantine should be used with caution in specific clinical situations.

Renal impairment: dose adjustment may be required in patients with reduced kidney function History of seizures: monitor closely for increased seizure activity Concurrent NMDA antagonists: avoid co‑administration to prevent additive CNS effects Cardiovascular disease: monitor blood pressure and heart rhythm during therapy Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant Store at ambient temperature: keep in original container, protect from moisture and direct sunlight

Memantine may interact with several medications; monitoring is advised.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity when combined - Other NMDA antagonists (e.g., ketamine): additive central nervous system depression - High‑dose quinidine: may raise memantine plasma concentrations

Moderate Interactions (Monitor Closely): - Anticholinergic agents: possible reduction in therapeutic benefit - Loop diuretics (e.g., furosemide): may increase memantine levels - CNS depressants (e.g., benzodiazepines): enhanced sedation or drowsiness